CommentTime to define the disorders of the syndrome of COPD
References (14)
- et al.
What have we learned from large drug treatment trials in COPD?
Lancet
(2007) - et al.
Sputum eosinophilia and short-term responses to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(2000) - et al.
From COPD to chronic systemic inflammatory syndrome?
Lancet
(2007) Global strategy for the diagnosis, management and prevention of COPD
Global strategy for asthma management and prevention 2008
- et al.
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Thorax
(2003) - et al.
Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up
Thorax
(2003)
Cited by (47)
There is still no established and accepted definition of COPD
2023, Respiratory MedicineWhole-genome methylation profiling from PBMCs in acute-exacerbation COPD patients with good and poor responses to corticosteroid treatment
2019, GenomicsCitation Excerpt :However, in some patients, the presence of several major COPD phenotypes might lead to difficulty in treatment, and thus the development of an objective standard to identify important subphenotypes is important. Many researchers have increasingly recognized COPD as heterogeneous disease [9,10] with several phenotypes, and others have proposed that COPD is actually a spectrum of obstructive airway diseases [11]. As personalized medicine is becoming a critical approach to medical care, pharmacogenetics and pharmacogenomics are recognized as essential steps towards achieving this kind of treatment.
Clinical, functional and therapeutic features of asthma in the elderly
2019, Revue Francaise d'AllergologieTreatment responsiveness of phenotypes of symptomatic airways obstruction in adults
2015, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The asthma-COPD overlap group7,18,21 has features of atopic asthma, with marked variability in airflow obstruction, emphysema, and chronic bronchitis in current smokers or exsmokers. This group had the most severe airflow obstruction, lies within the spectrum of the asthma-COPD overlap syndrome (ACOS),22 and is clinically important because it is associated with considerable morbidity and increased health care use, yet there is a limited evidence base for treatment.3 Typically, those in this overlap group are excluded from major asthma trials based on their smoking history and from major COPD trials because of their marked bronchodilator reversibility.6,23,24
An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials
2023, American Journal of Respiratory and Critical Care Medicine